Welcome & Introduction

Immunotherapy biomarkers in NSCLC

PD-L1 IHC testing landscape in NSCLC

Systemic Therapy Sequencing in Early Stage Resectable NSCLC

Durvalumab in stage III NSCLC Increasing hope for cure?

Immunotherapy in Fiest Line NSCLC

Introduction Non-small cell lung cancer

Role of VEGF Inhibitoe in NSCLC

Panel Discussion | Role of Immunotherapy in Lung Cancer

Closing Remarks